2025-12-30 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data you provided.

**0) Summary of Provided Data**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a multinational corporation specializing in pharmaceuticals, medical devices, and consumer packaged goods.
*   **Return vs. S&P 500 (VOO):** JNJ's cumulative return lags significantly behind the S&P 500.
*   **Alpha/Beta Analysis:** Alpha is consistently negative except for one period, indicating underperformance relative to market risk. Beta is generally low, suggesting lower volatility than the market.
*   **Recent Stock Price:** Current price is slightly below the 5-day and 20-day moving averages but above the 60-day moving average.
*   **Market Indicators:** MRI is high, RSI is neutral, and PPO is slightly negative. The hybrid signal suggests a predominantly buy recommendation.
*   **News:** Recent news focuses on a finalized acquisition, valuation perspectives, and drug trial updates.
*   **Analyst Opinion:** Overall, analysts have a "Buy" consensus with an average price target slightly above the current price.
*   **Earnings:** Both EPS and Revenue have fluctuated quarter by quarter.
*   **Financials:** Revenue and Profit Margins have been relatively stable. Equity has been increasing, with fluctuating ROE.

**1) Return Rate Comparison**

*   **JNJ Cumulative Return:** 60.02%
*   **VOO Cumulative Return:** 103.21%
*   **Divergence:** -41.8
*   **Relative Divergence:** 28.9

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period reflected in the cumulative returns. The divergence is substantial, and the relative divergence suggests it's closer to the lower end of its historical divergence range. This underperformance suggests that JNJ has not captured as much of the overall market growth as the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | 26.0%   | 66.8% | -2.0%   | -0.1  | 336.5  |
| 2016-2018  | 14.0%   | 10.7% | -1.0%   | 0.1   | 310.8  |
| 2017-2019  | 20.0%   | 71.5% | -2.0%   | 0.4   | 351.3  |
| 2018-2020  | 19.0%   | 79.2% | -4.0%   | 0.4   | 379.1  |
| 2019-2021  | 33.0%   | 79.2% | -14.0%  | 0.5   | 412.0  |
| 2020-2022  | 8.0%    | 79.6% | 9.0%    | 0.4   | 425.5  |
| 2021-2023  | -19.0%  | 79.6% | -20.0%  | 0.3   | 377.5  |
| 2022-2024  | -32.0%  | 79.6% | -53.0%  | 0.3   | 348.3  |
| 2023-2025  | 31.0%   | 79.6% | -37.0%  | 0.1   | 500.1  |

*   **CAGR (Compound Annual Growth Rate):** Varies significantly by period, showing both strong growth and significant decline.
*   **MDD (Maximum Drawdown):** Consistently high, indicating periods of significant losses.
*   **Alpha:** Mostly negative, meaning JNJ underperformed its expected return based on its beta and the market's return.  The period of 2020-2022 shows positive Alpha.
*   **Beta:** Generally low (around 0.1 to 0.5), indicating lower volatility than the overall market.
*   **Cap(B):**  Market capitalization has generally increased over time, showing overall growth in the company's value.

**Analysis:** The Alpha/Beta analysis suggests that JNJ has generally underperformed relative to the market risk, even when accounting for its lower volatility (Beta). The high Maximum Drawdown indicates significant risk of losses in certain periods. The positive alpha during 2020-2022, maybe due to the company being a leading company in the Covid-19 vaccinations.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 207.63
*   **Last Market Data:** Price: 207.56, Previous Close: 207.63, Change: -0.03
*   **5-day SMA:** 206.98
*   **20-day SMA:** 206.68
*   **60-day SMA:** 197.41

**Analysis:** The stock price is currently hovering around the 5-day and 20-day moving averages, suggesting a short-term period of consolidation. The fact that the price is well above the 60-day moving average indicates an overall upward trend in the medium term.

**3) Market Indicators & Expected Return**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 59.29 (Neutral)
*   **PPO:** -0.34 (Slightly Bearish)
*   **Hybrid Signal:** Cash_0%_Buy 90% of cash
*   **Recent Divergence Change:** -5.1 (Short-term decline)
*   **Expected Return:** -59.0%

**Analysis:**

*   The high MRI suggests that, based on this indicator alone, investment is recommended.
*   The RSI is neutral, indicating that the stock is neither overbought nor oversold.
*   The slightly negative PPO suggests a bearish trend, but the magnitude is small.
*   The recent negative change in relative divergence indicates a short-term downward trend.
*   The significantly negative Expected Return is a major concern, suggesting potential underperformance compared to the S&P 500 over the long term.

**4) Recent News & Significant Events**

*   **Halda Acquisition:** The finalized acquisition of Halda may positively impact future earnings.
*   **Valuation Perspectives:** Johnson & Johnson valuation perspectives after recent share price momentum
*   **Eczema Drug Trial Halt:** The halt of an eczema drug trial introduces uncertainty.
*   **Shares Surging:** Why shares of Johnson & Johnson are surging this month

**Analysis:** The news is a mixed bag. The acquisition of Halda and general surge in shares are positive catalysts. However, the halt of the eczema drug trial creates uncertainty.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (2.16 on a scale of 1-5)
*   **Target Price:** Average: 209.29, High: 240.00, Low: 155.00

**Analysis:** Analysts are generally optimistic about JNJ, with a "Buy" consensus and an average price target slightly above the current price. This suggests that analysts believe the stock has potential for growth. The wide range in target prices indicates some uncertainty.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-10-22 | 2.14 | 23.99 B$     |
| 2025-07-24 | 2.3  | 23.74 B$     |
| 2025-04-23 | 4.57 | 21.89 B$     |
| 2024-10-23 | 1.12 | 22.47 B$     |
| 2025-10-22 | 1.12 | 22.47 B$     |

**Analysis:** EPS and revenue have shown variability. The spike in EPS during 2025-04-23 is notable. The revenue has been fairly stable.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56%        |
| 2025-06-30 | $23.74B | 67.87%        |
| 2025-03-31 | $21.89B | 66.40%        |
| 2024-12-31 | $22.52B | 68.35%        |
| 2024-09-30 | $22.47B | 69.01%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-09-30 | $79.28B | 6.50%    |
| 2025-06-30 | $78.47B | 7.06%    |
| 2025-03-31 | $78.11B | 14.08%   |
| 2024-12-31 | $71.49B | 4.80%    |
| 2024-09-30 | $70.16B | 3.84%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been relatively stable, with a slight increase in the most recent quarter. Profit margins are consistently high, indicating strong profitability.
*   **Capital and Profitability:** Equity has been steadily increasing, demonstrating growth in the company's assets. ROE (Return on Equity) has fluctuated, with a significant spike in 2025-03-31.

**7) Comprehensive Analysis (Summary)**

Johnson & Johnson (JNJ) presents a mixed picture.

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 in terms of cumulative return. The negative alpha and expected return reinforce this underperformance.
*   **Volatility:** While JNJ has lower volatility than the overall market, it has high maximum drawdowns.
*   **Financial Stability:**  The company demonstrates financial stability with increasing equity and consistently high-profit margins.
*   **Recent Trends:** Recent analyst consensus and price action are positive, but the short-term divergence and slightly negative PPO suggest potential headwinds.
*   **Mixed News:** Recent news present a mix of the Halda Acquisition(positive), Shares Surging(positive), and the eczema drug trial halt(negative)

**Conclusion:**

JNJ may not be the best choice for investors seeking high growth or those heavily benchmarked against the S&P 500. However, its financial stability, potential for future growth with the Halda acquisition, and analyst optimism could be appealing to investors seeking a more conservative investment with potential for steady returns.  The negative expected return is a significant red flag that warrants further investigation.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.